We are analyzing https://link.springer.com/article/10.1007/s00198-012-1911-3.

Title:
The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy | Osteoporosis International
Description:
Summary The impact of intravenous bisphosphonate treatment to treat painful vertebral fractures in boys with DMD has not been documented. In this retrospective observational study of seven boys, 2 years of intravenous bisphosphonate therapy was associated with back pain improvement and stabilization or increases in the height ratios of fractured vertebrae. Introduction Boys with Duchenne muscular dystrophy (DMD) are at risk for vertebral fractures. We studied the impact of intravenous bisphosphonate therapy for the treatment of painful vertebral fractures in DMD. Methods This was a retrospective observational study in seven boys with DMD (median 11.6 years, range 8.5 to 14.3) treated with intravenous pamidronate (9 mg/kg/year) or zoledronic acid (0.1 mg/kg/year) for painful vertebral fractures. Results At baseline, 27 vertebral fractures were evident in the seven boys. After 2 years of bisphosphonate therapy, 17 of the fractures had an increase in the most severely affected vertebral height ratio, 10 vertebrae stabilized, and none showed a decrease in height ratio. Back pain resolved completely (N = 3) or improved (N = 4). The median change in lumbar spine volumetric bone mineral density Z-score was 0.5 standard deviations (interquartile range, −0.3 to 1.7). Two boys had three incident vertebral fractures in previously normal vertebral bodies that developed over the observation period. There was a decline in the trabecular bone formation rate on trans-iliac bone biopsy but no evidence of osteomalacia. First-dose side effects included fever and malaise (N = 4), hypocalcemia (N = 2), and vomiting (N = 1); there were no side effects with subsequent infusions. Conclusions Intravenous bisphosphonate therapy was associated with improvements in back pain and stabilization to improvement in vertebral height ratios of previously fractured vertebral bodies. At the same time, such therapy does not appear to completely prevent the development of new vertebral fractures in this context.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

article, google, scholar, pubmed, bone, cas, vertebral, fractures, muscular, dystrophy, duchenne, children, osteoporosis, boys, density, res, treatment, intravenous, therapy, rauch, mineral, study, pamidronate, miner, bisphosphonate, osteogenesis, imperfecta, glorieux, research, ward, effects, clin, child, privacy, cookies, content, data, dmd, years, access, bisphosphonates, arch, med, severe, pediatric, publish, search, treat, sbrocchi, impact,

Topics {✒️}

month download article/chapter iliac bone histomorphometry controlled dose-ranging study trans-iliac bone biopsy bone mineral density corticosteroid-induced osteoporosis randomized placebo-controlled study age-specific reference curves full article pdf adult bone density health statistics version duchenne muscular dystrophy privacy choices/manage cookies related subjects duchennes muscular dystrophy long-term effects intravenous zoledronic acid severe osteogenesis imperfecta painful vertebral fractures bone miner res de ridder ma incident vertebral fractures prevalent vertebral fractures low bone mass multinational bone study decreased bone turnover reduces bone turnover vertebral compression fractures improves skeletal architecture vertebral fracture assessment vertebral fracture diagnosis advanced vertebral fracture garn sm glorieux fh vertebral height ratios european economic area scope submit manuscript retrospective observational study gordon ke biggar wd grummer-strawn lm dietary reference intakes stanford university press paradoxical bilateral asymmetry body composition measured chesnut ch 3rd bianchi ml bisset gs 3rd pamidronate improves pain chronic neurological conditions

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy
         description:The impact of intravenous bisphosphonate treatment to treat painful vertebral fractures in boys with DMD has not been documented. In this retrospective observational study of seven boys, 2 years of intravenous bisphosphonate therapy was associated with back pain improvement and stabilization or increases in the height ratios of fractured vertebrae. Boys with Duchenne muscular dystrophy (DMD) are at risk for vertebral fractures. We studied the impact of intravenous bisphosphonate therapy for the treatment of painful vertebral fractures in DMD. This was a retrospective observational study in seven boys with DMD (median 11.6 years, range 8.5 to 14.3) treated with intravenous pamidronate (9 mg/kg/year) or zoledronic acid (0.1 mg/kg/year) for painful vertebral fractures. At baseline, 27 vertebral fractures were evident in the seven boys. After 2 years of bisphosphonate therapy, 17 of the fractures had an increase in the most severely affected vertebral height ratio, 10 vertebrae stabilized, and none showed a decrease in height ratio. Back pain resolved completely (N = 3) or improved (N = 4). The median change in lumbar spine volumetric bone mineral density Z-score was 0.5 standard deviations (interquartile range, −0.3 to 1.7). Two boys had three incident vertebral fractures in previously normal vertebral bodies that developed over the observation period. There was a decline in the trabecular bone formation rate on trans-iliac bone biopsy but no evidence of osteomalacia. First-dose side effects included fever and malaise (N = 4), hypocalcemia (N = 2), and vomiting (N = 1); there were no side effects with subsequent infusions. Intravenous bisphosphonate therapy was associated with improvements in back pain and stabilization to improvement in vertebral height ratios of previously fractured vertebral bodies. At the same time, such therapy does not appear to completely prevent the development of new vertebral fractures in this context.
         datePublished:2012-02-02T00:00:00Z
         dateModified:2012-02-02T00:00:00Z
         pageStart:2703
         pageEnd:2711
         sameAs:https://doi.org/10.1007/s00198-012-1911-3
         keywords:
            Bisphosphonates
            Bone histomorphometry
            Bone mineral density
            Clinical/pediatrics
            Corticosteroid osteoporosis
            Vertebral fractures
            Orthopedics
            Endocrinology
            Rheumatology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-012-1911-3/MediaObjects/198_2012_1911_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-012-1911-3/MediaObjects/198_2012_1911_Fig2_HTML.gif
         isPartOf:
            name:Osteoporosis International
            issn:
               1433-2965
               0937-941X
            volumeNumber:23
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:A. M. Sbrocchi
               affiliation:
                     name:Children’s Hospital of Eastern Ontario
                     address:
                        name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Rauch
               affiliation:
                     name:Shriners Hospital for Children
                     address:
                        name:Genetics Unit, Shriners Hospital for Children, Montreal, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:P. Jacob
               affiliation:
                     name:Children’s Hospital of Eastern Ontario
                     address:
                        name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. McCormick
               affiliation:
                     name:Children’s Hospital of Eastern Ontario
                     address:
                        name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:H. J. McMillan
               affiliation:
                     name:Children’s Hospital of Eastern Ontario
                     address:
                        name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. A. Matzinger
               affiliation:
                     name:Children’s Hospital of Eastern Ontario
                     address:
                        name:Department of Diagnostic Imaging, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:L. M. Ward
               affiliation:
                     name:Children’s Hospital of Eastern Ontario
                     address:
                        name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy
      description:The impact of intravenous bisphosphonate treatment to treat painful vertebral fractures in boys with DMD has not been documented. In this retrospective observational study of seven boys, 2 years of intravenous bisphosphonate therapy was associated with back pain improvement and stabilization or increases in the height ratios of fractured vertebrae. Boys with Duchenne muscular dystrophy (DMD) are at risk for vertebral fractures. We studied the impact of intravenous bisphosphonate therapy for the treatment of painful vertebral fractures in DMD. This was a retrospective observational study in seven boys with DMD (median 11.6 years, range 8.5 to 14.3) treated with intravenous pamidronate (9 mg/kg/year) or zoledronic acid (0.1 mg/kg/year) for painful vertebral fractures. At baseline, 27 vertebral fractures were evident in the seven boys. After 2 years of bisphosphonate therapy, 17 of the fractures had an increase in the most severely affected vertebral height ratio, 10 vertebrae stabilized, and none showed a decrease in height ratio. Back pain resolved completely (N = 3) or improved (N = 4). The median change in lumbar spine volumetric bone mineral density Z-score was 0.5 standard deviations (interquartile range, −0.3 to 1.7). Two boys had three incident vertebral fractures in previously normal vertebral bodies that developed over the observation period. There was a decline in the trabecular bone formation rate on trans-iliac bone biopsy but no evidence of osteomalacia. First-dose side effects included fever and malaise (N = 4), hypocalcemia (N = 2), and vomiting (N = 1); there were no side effects with subsequent infusions. Intravenous bisphosphonate therapy was associated with improvements in back pain and stabilization to improvement in vertebral height ratios of previously fractured vertebral bodies. At the same time, such therapy does not appear to completely prevent the development of new vertebral fractures in this context.
      datePublished:2012-02-02T00:00:00Z
      dateModified:2012-02-02T00:00:00Z
      pageStart:2703
      pageEnd:2711
      sameAs:https://doi.org/10.1007/s00198-012-1911-3
      keywords:
         Bisphosphonates
         Bone histomorphometry
         Bone mineral density
         Clinical/pediatrics
         Corticosteroid osteoporosis
         Vertebral fractures
         Orthopedics
         Endocrinology
         Rheumatology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-012-1911-3/MediaObjects/198_2012_1911_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-012-1911-3/MediaObjects/198_2012_1911_Fig2_HTML.gif
      isPartOf:
         name:Osteoporosis International
         issn:
            1433-2965
            0937-941X
         volumeNumber:23
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:A. M. Sbrocchi
            affiliation:
                  name:Children’s Hospital of Eastern Ontario
                  address:
                     name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Rauch
            affiliation:
                  name:Shriners Hospital for Children
                  address:
                     name:Genetics Unit, Shriners Hospital for Children, Montreal, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:P. Jacob
            affiliation:
                  name:Children’s Hospital of Eastern Ontario
                  address:
                     name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. McCormick
            affiliation:
                  name:Children’s Hospital of Eastern Ontario
                  address:
                     name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:H. J. McMillan
            affiliation:
                  name:Children’s Hospital of Eastern Ontario
                  address:
                     name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. A. Matzinger
            affiliation:
                  name:Children’s Hospital of Eastern Ontario
                  address:
                     name:Department of Diagnostic Imaging, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:L. M. Ward
            affiliation:
                  name:Children’s Hospital of Eastern Ontario
                  address:
                     name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Osteoporosis International
      issn:
         1433-2965
         0937-941X
      volumeNumber:23
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Children’s Hospital of Eastern Ontario
      address:
         name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
         type:PostalAddress
      name:Shriners Hospital for Children
      address:
         name:Genetics Unit, Shriners Hospital for Children, Montreal, Canada
         type:PostalAddress
      name:Children’s Hospital of Eastern Ontario
      address:
         name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
         type:PostalAddress
      name:Children’s Hospital of Eastern Ontario
      address:
         name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
         type:PostalAddress
      name:Children’s Hospital of Eastern Ontario
      address:
         name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
         type:PostalAddress
      name:Children’s Hospital of Eastern Ontario
      address:
         name:Department of Diagnostic Imaging, Children’s Hospital of Eastern Ontario, Ottawa, Canada
         type:PostalAddress
      name:Children’s Hospital of Eastern Ontario
      address:
         name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:A. M. Sbrocchi
      affiliation:
            name:Children’s Hospital of Eastern Ontario
            address:
               name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:F. Rauch
      affiliation:
            name:Shriners Hospital for Children
            address:
               name:Genetics Unit, Shriners Hospital for Children, Montreal, Canada
               type:PostalAddress
            type:Organization
      name:P. Jacob
      affiliation:
            name:Children’s Hospital of Eastern Ontario
            address:
               name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:A. McCormick
      affiliation:
            name:Children’s Hospital of Eastern Ontario
            address:
               name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:H. J. McMillan
      affiliation:
            name:Children’s Hospital of Eastern Ontario
            address:
               name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:M. A. Matzinger
      affiliation:
            name:Children’s Hospital of Eastern Ontario
            address:
               name:Department of Diagnostic Imaging, Children’s Hospital of Eastern Ontario, Ottawa, Canada
               type:PostalAddress
            type:Organization
      name:L. M. Ward
      affiliation:
            name:Children’s Hospital of Eastern Ontario
            address:
               name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
      name:Genetics Unit, Shriners Hospital for Children, Montreal, Canada
      name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
      name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
      name:Division of Neurology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
      name:Department of Diagnostic Imaging, Children’s Hospital of Eastern Ontario, Ottawa, Canada
      name:Division of Endocrinology, Children’s Hospital of Eastern Ontario, Ottawa, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(167)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.15s.

LINK . SPRINGER . COM {}